Metabolic syndrome and localization of white matter hyperintensities in the elderly population.

Florence Portet, Adam M. Brickman, Yaakov Stern, Nikolaos Scarmeas, Jordan Muraskin, Frank A. Provenzano, Claudine Berr, Alain Bonafé, Sylvaine Artero, Karen Ritchie, et al.

APPENDIX

Table A: Factors associated with total WMH volumes categorized in tertiles

	WMH volumes		
	Low levels (<0.7 mL)	High levels (≥0.7 mL)	p-value
Median, (25^{th} -50^{th} percentile)	0.30, (0.10-0.40)	1.75, (0.80-1.75)	
Women, %	53.7	52.0	0.76
Age, m (SD)	70.2 (3.7)	72.1 (4.1)	$<10^{-4}$
No academic qualification /primary school, %	17.5	19.6	0.85
Current smokers, %	7.5	8.8	0.92
Use of lipid lowering drugs, %	22.5	25.0	0.60
Performances in MMSE, m (SD)	27.8 (1.4)	27.5 (1.6)	0.10
ApoE4 genotype (heterozygote), %	17.5	23.6	0.18
Total cranial volume (ml), m (SD)	1460.6 (127.0)	1467.7(129.3)	0.63

MMSE: mini mental state examination; ApoE4: ε4 allele of the Apolipoprotein E (having at least one copy), WMH: white mater hyperintensities.
M (SD): means (standard deviation)

Table B: Association between each MetS components and total WMH volumes.

		Levels of WMH volumes	
MetS criteria	Total n, % exposed	OR (95% CI) of having high levels of WMH volumes (≥0.7mL)*	p
Central obesity	292, 18.1%	1.57 (0.84;2.94)	0.16
High Triglycerides	308, 14.9%	1.25 (0.65; 2.39)	0.50
Low HDL-cholesterol	308, 8.1%	1.81 (0.77;4.27)	0.17
Hypertension	304, 80.6%	1.87 (1.00; 3.50)	0.05
High FBG	324, 9.4%	1.14 (0.51; 2.56)	0.75
Number of MetS criteria	288	1.31 (1.01-1.71)	0.04

WMH: White matter hyperintensities, MetS: Metabolic Syndrome, HDL: high density lipoprotein, FBG : Fasting Blood Glucose

OR (95% CI) : odds ratio accompanied with its 95% confidence interval,

* Odds ratio adjusted for age at baseline (by year), sex, educational attainment, smoking, use of lipids lowering drugs MMSE scores, allele ε4 of apolipoprotein E and total cranial volume - Results of logistic regression models -